New research published in the New England Journal of Medicine reveals that nearly half of follicular lymphoma patients treated with CAR T-cell therapy were still lymphoma-free a decade later.
—
What the Research Found
A landmark study tracking 38 patients over ten years has shown that CAR T-cell therapy — a form of treatment that uses a patient’s own immune cells, re-engineered in a laboratory to hunt and destroy cancer — can deliver lasting results for people with blood cancers that had stopped responding to other treatments.
The figures are striking. Among patients with large B-cell lymphoma, 32% were free of their disease at the ten-year mark. For those with follicular lymphoma, that figure rose to 47%.
Both groups had relapsed or refractory disease — meaning their cancer had either come back or had never responded to standard treatment. For many of these patients, options were running out.
Why This Matters for Blood Cancer Patients
CAR T-cell therapy — short for chimeric antigen receptor T-cell therapy — works by removing white blood cells from a patient, modifying them genetically so they can recognise and attack cancer cells, then infusing them back into the body. It is not a tablet or a course of radiotherapy. It is a bespoke, living treatment built from the patient’s own biology.
Until now, long-term data on its effectiveness has been limited. Ten-year survival figures from a single study cohort are rare in oncology research. The New England Journal of Medicine, which published the findings, is one of the most respected medical journals in the world — so the data carries weight.
But it’s worth being clear about what this study is and isn’t. Thirty-eight patients is a small group. These are early, pioneering cases. The results are encouraging, not conclusive.
The Numbers in Plain English
Put simply: roughly one in three large B-cell lymphoma patients in this study were still cancer-free after a decade. For follicular lymphoma patients, it was closer to one in two.
According to the New England Journal of Medicine, these are patients who had already exhausted other lines of treatment. The fact that any proportion remained lymphoma-free at ten years is, according to the researchers behind the study, a meaningful finding in a field where long-term data has historically been hard to come by.
What Happens Next
CAR T-cell therapy is already available through NHS England for certain blood cancer patients, though access depends on specific eligibility criteria and is delivered through specialist centres. Patients in Kent who are being treated for lymphoma should speak to their haematology team about whether this or similar therapies might be relevant to their care pathway.
Larger trials with bigger patient groups will be needed before the full picture becomes clear. But for patients and families living with relapsed or refractory lymphoma, ten-year survival data — however early — offers something that can be hard to find: evidence that long-term remission is possible.
—
Source: @NEJM
Key Takeaways
- Among 38 patients treated with CAR T-cell therapy, 32% of those with large B-cell lymphoma and 47% with follicular lymphoma were lymphoma-free at ten years
- All patients in the study had relapsed or refractory B-cell lymphomas — cancers that had returned or failed to respond to earlier treatment
- The findings were published in the New England Journal of Medicine, one of the world’s leading peer-reviewed medical journals
—
What This Means for Kent Residents
Kent patients being treated for lymphoma or other blood cancers should raise this research with their GP or hospital specialist if they want to understand whether CAR T-cell therapy could be relevant to their situation — access through the NHS depends on individual clinical criteria, and a consultant haematologist is best placed to advise. NHS England does commission CAR T-cell therapy for eligible patients at specialist centres, so it is not simply a treatment available only in clinical trials. For anyone concerned about symptoms such as persistent swollen glands, unexplained fatigue, or night sweats — all of which can be associated with lymphoma — the NHS advises contacting your GP promptly, or calling NHS 111 if you need urgent guidance outside surgery hours.